Losartan in diabetic nephropathy

Expert Review of Cardiovascular Therapy
Norberto PericoGiuseppe Remuzzi

Abstract

Diabetic nephropathy has become the single most important cause of end-stage renal disease in the USA, Europe and Japan. The earliest marker of incipient diabetic nephropathy is the transition of normoalbuminuria to microalbuminuria at an albumin excretion rate of 20 microg/min. Human studies in patients both with and without diabetic kidney diseases have shown that the severity of baseline proteinuria is an important predictor of the rate of loss of renal function. Moreover, the reduction in protein excretion rate when patients with nephropathies are being treated with antihypertensive agents predicts the efficacy of subsequent renoprotection. Experimental and clinical observations provide the rationale for targeting the renin-angiotensin system as a renoprotective approach in diabetic and nondiabetic proteinuric nephropathies. Losartan (Cozaar, Merck Sharpe and Dohme) is a potent, orally active and highly specific angiotensin-type 1 receptor blocker. In addition to its antihypertensive efficacy, losartan decreases the left ventricular mass index in patients with hypertension, left ventricular end-diastolic and end-systolic volume in subjects with heart failure and prevents cardiovascular morbidity and death, predominantly str...Continue Reading

References

Oct 18, 1976·JAMA : the Journal of the American Medical Association·M J KussmanR E Gleason
Apr 1, 1991·Hypertension·N E RhalebD Regoli
Jul 22, 1989·BMJ : British Medical Journal·H H Parving, E Hommel
Jan 1, 1985·Uremia Investigation·C E MogensenB Feldt-Rasmussen
Feb 1, 1994·Kidney International·W KrizB Hähnel
Feb 1, 1996·Kidney International·J Egido
Jan 1, 1997·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·D C Wheeler
Jun 1, 1997·The Journal of Clinical Investigation·J GloyH Pavenstädt
Sep 12, 1998·Kidney International·D W JohnsonC A Pollock
Nov 13, 1998·The New England Journal of Medicine·G Remuzzi, T Bertani
Jun 3, 1999·Kidney & Blood Pressure Research·F Strutz, G A Müller
Jul 27, 1999·Proceedings of the Association of American Physicians·G WolfR A Stahl
May 10, 2000·Drugs & Aging·K L Simpson, K J McClellan
Jun 27, 2000·Diabetes Care·R R Little
Jul 8, 2000·Clinical Pharmacokinetics·D A SicaW F Keane
Jan 6, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·G Wolf
Feb 13, 2001·Kidney International·P HovindH H Parving
Mar 29, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·H ButerP E de Jong
May 30, 2001·Lancet·P RuggenentiG Remuzzi
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group

❮ Previous
Next ❯

Citations

Nov 1, 2007·International Journal of Clinical Practice·M Volpe
May 3, 2005·Journal of Medical Genetics·M R AbdollahiI N M Day
Dec 17, 2004·American Journal of Physiology. Cell Physiology·Amy K L BanesMario B Marrero

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.